Results 31 to 40 of about 98,415 (200)

Treatment of type 2 diabetes by free fatty acid receptor agonists [PDF]

, 2014
Dietary free fatty acids (FFAs), such as ω-3 fatty acids, regulate metabolic and anti-inflammatory processes, with many of these effects attributed to FFAs interacting with a family of G protein-coupled receptors.
Hudson, Brian D., Milligan, Graeme, Ulven, Trond, Watterson, Kenneth R.   +3 more
core   +2 more sources

Glucagon‐like peptide‐1 acutely affects renal blood flow and urinary flow rate in spontaneously hypertensive rats despite significantly reduced renal expression of GLP‐1 receptors

Physiological Reports, 2017
Glucagon‐like peptide‐1 (GLP‐1) is an incretin hormone increasing postprandial insulin release. GLP‐1 also induces diuresis and natriuresis in humans and rodents. The GLP‐1 receptor is extensively expressed in the renal vascular tree in normotensive rats
Jonas Ronn, Elisa P. Jensen, Nicolai J. Wewer Albrechtsen, Jens Juul Holst, Charlotte M. Sorensen   +4 more
doaj   +1 more source

Insulin–glucagon‐like peptide‐1 receptor agonist relay and glucagon‐like peptide‐1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open‐label trial study

Journal of Diabetes Investigation, 2022
Aims/Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) might be less effective in patients with severe hyperglycemia, because hyperglycemia downregulated the GLP‐1 receptor in an animal study.
Yumie Takeshita, Yuki Kita, Takeo Tanaka, Hisanori Goto, Yujiro Nakano, Chisato Teramura, Yasufumi Enyama, Toshinari Takamura, the Establishment of Rationale for Antiaging Diabetic Medicine (ERA‐DM) Study Group   +8 more
doaj   +1 more source

Allosteric optical control of a class B G-protein-coupled receptor [PDF]

, 2016
Allosteric regulation promises to open up new therapeutic avenues by increasing drug specificity at G‐protein‐coupled receptors (GPCRs). However, drug discovery efforts are at present hampered by an inability to precisely control the allosteric site ...
Broichhagen, Broichhagen, Broichhagen, Broichhagen, Campbell, Chen, Gefel, Gromada, Holz, Holz, Holz, Inzucchi, Nolan, Nolte, Parker, Pittolo, Thorens, Velema, Volgraf, Willard, Wootten   +20 more
core   +1 more source

Insulin-like growth factor-1 is a negative modulator of glucagon secretion [PDF]

, 2017
Glucagon secretion involves a combination of paracrine, autocrine, hormonal, and autonomic neural mechanisms. Type 2 diabetes often presents impaired glucagon suppression by insulin and glucose.
Andreozzi, F, Di Fatta, C, Fuoco, A, Mancuso, E, Mannino, Gc, Sesti, G, Spiga, R   +6 more
core   +1 more source

Extracellular loops 2 and 3 of the calcitonin receptor selectively modify agonist binding and efficacy. [PDF]

, 2018
Class B peptide hormone GPCRs are targets for the treatment of major chronic disease. Peptide ligands of these receptors display biased agonism and this may provide future therapeutic advantage.
Andreassen, Arthur Christopoulos, Baldwin, Barwell, Belcheva, Berendsen, Black, Booe, Caroline A. Hick, Christopher A. Reynolds, Christopoulos, Christopoulos, Cosman, Dal Maso, de Graaf, Debbie L. Hay, Dehua Yang, Denise Wootten, Doerr, Dolinsky, Dong, Dong, Emma Dal Maso, Epand, Essmann, Eswar, Feyen, Furness, Gingell, Giuseppe Deganutti, Hamelryck, Harikumar, Harvey, Hay, Hilton, Huang, Humphrey, Johansson, Jorgensen, Koole, Koole, Krautler, Kuestner, Kuwasako, Kuwasako, Langston, Li, Liang, Lomize, Loncharich, Ming-Wei Wang, Minhas, Morfis, Orlowski, Patrick M. Sexton, Poyner, Sebastian G.B. Furness, Sommer, Udawela, Udawela, Vi Pham, Watkins, Weaver, Weston, Weston, Woolley, Woolley, Wootten, Wootten, Yue Zhu, Zhang   +70 more
core   +1 more source

The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis.

PLoS ONE, 2015
AimsTo determine the effects of glucagon-like peptide-1 receptor agonists compared with placebo and other anti-diabetic agents on weight loss in overweight or obese patients with type 2 diabetes mellitus.MethodsElectronic searches were conducted for ...
Jessica E Potts, Laura J Gray, Emer M Brady, Kamlesh Khunti, Melanie J Davies, Danielle H Bodicoat   +5 more
doaj   +1 more source

Liraglutide Attenuates Aortic Valve Calcification in a High-Cholesterol-Diet-Induced Experimental Calcific Aortic Valve Disease Model in Apolipoprotein E-Deficient Mice

Journal of Cardiovascular Development and Disease, 2023
Background: Calcific aortic valve disease (CAVD) is a significant cause of morbidity and mortality among elderly people. However, no effective medications have been approved to slow or prevent the progression of CAVD.
Yangzhao Zhou, Zhaoshun Yuan, Min Wang, Zhiyuan Zhang, Changming Tan, Jiaolian Yu, Yanfeng Bi, Xiaobo Liao, Xinmin Zhou, Md Sayed Ali Sheikh, Dafeng Yang   +10 more
doaj   +1 more source

Intestinal gene expression in pigs: effects of reduced feed intake during weaning and potential impact of dietary components [PDF]

, 2011
The weaning transition is characterised by morphological, histological and microbial changes, often leading to weaning-associated disorders. These intestinal changes can partly be ascribed to the lack of luminal nutrition arising from the reduced feed ...
Bauer, E., Metzler-Zebeli, B.U., Mosenthin, R., Verstegen, M.W.A.   +3 more
core   +1 more source

Characterization of glucagon-like peptide-1 receptor-binding determinants [PDF]

Journal of Molecular Endocrinology, 2000
Glucagon-like peptide 1 (GLP-1) is a potent insulinotropic hormone currently under study as a therapeutic agent for type 2 diabetes. Since an understanding of the molecular mechanisms leading to high-affinity receptor (R) binding and activation may facilitate the development of more potent GLP-1R agonists, we have localized specific regions of GLP-1R ...
Q, Xiao, W, Jeng, M B, Wheeler
openaire   +2 more sources